Accès ouvert
2026
preprint
OpenAlex
Howook Hwang, Mee Y. Shelley, Andrew Placzek, Kevin R. DeMarco et autres
The development of a small-molecule suitable for clinical use involves optimization of ligand binding to an identified target protein but also frequently the reduction of binding to a variety of anti-target proteins known to pose translational risk. These anti-targets, often referred to …
us, gb
(code pays fourni par la source)
Accès ouvert
2026
preprint
OpenAlex
Howook Hwang, Mee Y. Shelley, Andrew Placzek, Kevin R. DeMarco et autres
The development of a small-molecule suitable for clinical use involves optimization of ligand binding to an identified target protein but also frequently the reduction of binding to a variety of anti-target proteins known to pose translational risk. These anti-targets, often referred to …
us, gb
(code pays fourni par la source)
Accès ouvert
2026
preprint
OpenAlex
Howook Hwang, Mee Y. Shelley, Andrew Placzek, Kevin R. DeMarco et autres
The development of a small-molecule suitable for clinical use involves optimization of ligand binding to an identified target protein but also frequently the reduction of binding to a variety of anti-target proteins known to pose translational risk. These anti-targets, often referred to …
us, gb
(code pays fourni par la source)
2024
article
OpenAlex
Pieter H. Bos, Fabio Ranalli, E. A. Flood, Shawn Watts et autres
The hit identification stage of a drug discovery program generally involves the design of novel chemical scaffolds with desired biological activity against the target(s) of interest. One common approach is scaffold hopping, which is the manual design of novel scaffolds based on …
us
(code pays fourni par la source)
Accès ouvert
2024
preprint
OpenAlex
Pieter H. Bos, Fabio Ranalli, E. A. Flood, Shawn Watts et autres
The hit identification stage of a drug discovery program generally involves the design of novel chemical scaffolds with desired biological activity against the target(s) of interest. One common approach is scaffold hopping, which is the manual design of novel scaffolds based on …
us
(code pays fourni par la source)
Accès ouvert
2024
preprint
OpenAlex
Pieter H. Bos, Fabio Ranalli, E. A. Flood, Shawn Watts et autres
The hit identification stage of a drug discovery program generally involves the design of novel chemical scaffolds with desired biological activity against the target(s) of interest. One common approach is scaffold hopping, which is the manual design of novel scaffolds based on …
us
(code pays fourni par la source)
Accès ouvert
2020
article
OpenAlex
Alexander L. Perryman, Daigo Inoyama, Jimmy S. Patel, Sean Ekins et autres
Solubility is a key metric for therapeutic compounds. Conversely, insoluble compounds cloud the accuracy of assays at all stages of chemical biology and drug discovery. Herein, we disclose naïve Bayesian classifier models to predict aqueous solubility. Publicly accessible aqueous solubility data were …
us, no
(code pays fourni par la source)
Accès ouvert
2020
article
OpenAlex
Daigo Inoyama, Divya Awasthi, Glenn C. Capodagli, Kholiswa Tsotetsi et autres
us
(code pays fourni par la source)
2020
article
OpenAlex
Joel S. Freundlich, David Alland, Matthew B. Neiditch, Glenn C. Capodagli et autres
Accès ouvert
2019
article
OpenAlex
Xin Wang, Daigo Inoyama, Riccardo Russo, Shao-Gang Li et autres
us
(code pays fourni par la source)
Accès ouvert
2019
article
OpenAlex
Evan J. Waldron, Daniel J. Snyder, Nicolas L. Fernandez, Emily Sileo et autres
The diffusible signal factors (DSFs) are a family of quorum-sensing autoinducers (AIs) produced and detected by numerous gram-negative bacteria. The DSF family AIs are fatty acids, differing in their acyl chain length, branching, and substitution but having in common a cis-2 double …
us
(code pays fourni par la source)
Accès ouvert
2018
article
OpenAlex
Pradeep Kumar, Glenn C. Capodagli, Divya Awasthi, Riju Shrestha et autres
Cell wall biosynthesis inhibitors have proven highly effective for treating tuberculosis (TB). We discovered and validated members of the indazole sulfonamide class of small molecules as inhibitors of Mycobacterium tuberculosis KasA—a key component for biosynthesis of the mycolic acid layer of the …
us
(code pays fourni par la source)